Nanoparticle tracking analysis is an excellent tool for the characterization of mono- and polydisperse nanoparticle systems within the 10-2000 nm size range. The suitability of this technique relies on its ability to track all particles in solution simultaneously based on their Brownian motion giving an accurate size distribution. The tracked rate of particle movement is related to the particle's hydrodynamic radius using the Stokes-Einstein equation for determining the size distribution. Here we describe the characterization β-casein nanocarriers encapsulating a model hydrophobic compound, 8-anilino-1-naphthalenesulfonic acid, and the natural bioactive curcumin using the Malvern NanoSight NS300. Utilizing both normal light scattering and fluorescent modes of the NS300 enabled the differentiation of particles that had encapsulated the two fluorescent molecules and provided an accurate size distribution of the nanocarriers.

01 Mar 2006·International Journal of PharmaceuticsQ2 · MEDICINE

Evaluation of rapidly disintegrating tablets containing glycine and carboxymethylcellulose

Q2 · MEDICINE

Article

Author: Yasuo Yoshihashi ; Jinichi Fukami ; Katsuhide Terada ; Etsuo Yonemochi

A rapidly disintegration tablet in the oral cavity was prepared using a glycine as a disintegrant. Effect of disintegrant on the disintegration behavior of the tablet in the oral cavity was evaluated. Wetting time prepared from carboxymethylcellulose (NS-300) having the hardness of 4 kg was 3 s. Tablet containing NS-300 showed fastest disintegration compared to other formulations. These results suggested that NS-300 possessed excellent wetting nature and resulted in the rapid disintegration of tablet. Ethenzamide and ascorbic acid were added to the formulation, and their disintegration behavior were evaluated. Ethenzamide did not affect the disintegration property, however, ascorbic acid prolonged disintegration time. It was suggested that the tablet formulation containing NS-300 and glycine was highly applicable to water-insoluble drug, such as ethenzamide.

01 Dec 2003·AAPS PharmSciTechQ3 · MEDICINE

Design of rapidly disintegrating oral tablets using acid-treated yeast cell wall: A technical note

Q3 · MEDICINE

Article

Author: Yuuki Takashima ; Tetsuya Ozeki ; Hiroshi Yuasa ; Takahide Kasai ; Hiroaki Okada ; Hideyo Katsuyama ; Takahiro Eguchi ; Hisaya Kakiuchi ; Yuriko Yasuzawa

A study was conducted to examine the ability of four disintegrants mixed with granules consisting of 5% acidified yeast cell wall (AYC), used as a binder during granulation, and acetylsalicylic acid (ASA) as a model drug to further decrease disintegration rates.The D₅₀ value of ASA granulated with 5% AYC was approx. 80 μm.The mixture of the granules and 10% disintegrant was compressed into tablets at 100 MPa by external lubrication.NS300 (CM-cellulose) is hydrophilic but has low swelling ability and plays a role in absorbing water into tablets and is called wicking type.The disintegration time of tablets containing 10% NS300 compressed at 100 MPa in the mouths of 5 healthy adult volunteers was measured.Complete disintegration was achieved at 20.2, 20.5, 19.9, 16.6, and 23.1 s, resp.These results showed that these features afford high utility as an oral drug delivery system.

100 Deals associated with NS-300

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autistic Disorder	Preclinical	South Korea	Neuracle Science Co., Ltd.	-
Epilepsy	Preclinical	South Korea	Neuracle Science Co., Ltd.	-
Neuralgia	Preclinical	South Korea	Neuracle Science Co., Ltd.	-
Schizophrenia	Preclinical	South Korea	Neuracle Science Co., Ltd.	-
Sensation Disorders	Discovery	United States	Neuracle Science Co., Ltd.	01 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

NS-300

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation